150 likes | 407 Views
Sponsored through an unrestricted educational grant from Novartis Pharmaceutical Ltd to help support the cost of developing and hosting this educational workshop series . Background. 65 y old malePast history of hypertension and cerebro-vascular diseaseJuly 2003Aortic aneurysm and complicationsEndovascular aortic aneurysm repair (EVAR)post-operative bleed requiring laparotomyparaparesis secondary to spinal cord ischaemialong term suprapubic catheterlongstanding sacral pressure sores.
E N D
2. Sponsored through an unrestricted educational grant from Novartis Pharmaceutical Ltd to help support the cost of developing and hosting this educational workshop series
3. Background 65 y old male
Past history of hypertension and cerebro-vascular disease
July 2003
Aortic aneurysm and complications
Endovascular aortic aneurysm repair (EVAR)
post-operative bleed requiring laparotomy
paraparesis secondary to spinal cord ischaemia
long term suprapubic catheter
longstanding sacral pressure sores
4. July 2007 Admitted with fever four years after aneurysm repair
Blood cultures MRSA (isolate 1)
X-ray pelvis and transoesophageal echocardiogram (TOE) normal
2 weeks iv vancomycin plus oral rifampicin, then stopped
Question:
What was the source of infection?
How would you have treated it?
5. July 2007 5 days later- pyrexia
MRSA again in blood cultures (isolate 2)
Re-started vancomycin plus rifampicin for 4 weeks
Home on doxycycline plus rifampicin for a further 4 weeks
6. November 2007 re-admitted with fever and back pain after 9 days at home
Blood cultures MRSA (isolate 3)
Transthoracic echocardiogram (TTE) normal
Magnetic resonance imaging (MRI) spine - normal
WCC scan suggestive of increased uptake in lower vertebra
1 week vancomycin, then MIC for MRSA strain reported as 3 mg/L
intravenous linezolid for 10 days, then home on further 4 weeks oral
8. Population analysis of GISA
9. January 2008 re-admitted in septic shock, day 38 linezolid
MRSA in blood (isolate 4)
intravenous daptomycin - five fold rise in CK, therefore stopped (was on a statin at the same time)
blood cultures MRSA (isolate 5)
Quinupristin/dalfopristin plus fusidic acid for 12 weeks
10. Late February 2008 Blood cultures sterile by week 3 of quinupristin/dalfopristin plus fusidic acid
inflammatory markers settling
Computerised axial tomography (CT) scan at week 7 increased thickness of aneurysm wall compared to previous scans
12. April 2008 Cardiothoracic review - no surgical intervention indicated
11 weeks into quinupristin/dalfopristin treatment
septic again
ESBL-producing E. coli in urine and femoral line tip
meropenem for 10 days
quinupristin/dalfopristin discontinued end of 12 weeks
blood cultures just before quinupristin/dalfopristin stopped MRSA (isolate 6)
13. April 2008 Quinupristin/dalfopristin re-started (1 week later) plus daptomycin 4mg/kg
CK levels remain normal
2 weeks - Quinupristin/dalfopristin switched to gentamicin and daptomycin dose increased to 10mg/kg
new femoral line
14. Mid-July 2008 Gentamicin stopped after 4 weeks
MRSA bacteraemia persists (isolate 7)
8 weeks into daptomycin treatment - progressive rise in MIC
daptomycin MIC 0.125 mg/L initially, but peaked at 12.0 mg/L
Isolates now also resistant to rifampicin and fusidic acid
Positron emission tomography (PET) scan confirms aortic graft infection
16. End-July 2008 Aortic graft replaced
Cultures of graft are negative, but S. aureus identified by 16s rDNA PCR
Given iv linezolid, then oral fosfomycin, doxycycline plus chloamphenicol for 4 weeks
End-August 2008
switched to oral doxycycline alone
12 sets of blood cultures negative as at 1 Oct 2008